TSC
ESPR

Two Seas Capital’s Esperion Therapeutics ESPR Stock Holding History

Two Seas Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,394,833
Closed -$31.2M – 50
2026
Q1 		$31.2M Sell
11,394,833
-507,688
-4% -$1.61M 0.44% 24
2025
Q4 		$44M Buy
11,902,521
+2,152,797
+22% +$6.96M 0.91% 18
2025
Q3 		$25.8M Sell
9,749,724
-205,251
-2% -$397K 0.41% 25
2025
Q2 		$9.8M Buy
9,954,975
+3,024,104
+44% +$3.03M 0.16% 26
2025
Q1 		$9.98M Buy
6,930,871
+700,000
+11% +$1.29M 0.31% 19
2024
Q4 		$13.7M Sell
6,230,871
-353,407
-5% -$824K 1.18% 15
2024
Q3 		$10.9M Buy
6,584,278
+848,618
+15% +$1.71M 1.76% 12
2024
Q2 		$12.7M Buy
5,735,660
+1,570,003
+38% +$3.69M 2.07% 11
2024
Q1 		$11.2M Sell
4,165,657
-3,520,463
-46% -$8.55M 2.19% 9
2023
Q4 		$23M Buy
7,686,120
+13,950
+0.2% +$18.1K 5.61% 3
2023
Q3 		$7.52M Buy
7,672,170
+4,730,298
+161% +$6.84M 1.51% 8
2023
Q2 		$4.09M Buy
+2,941,872
New +$4.11M 0.89% 6

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Two Seas Capital's ESPR Position: Q2 2026 in Review

Two Seas Capital sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 11,394,833 shares — an estimated $31.2M sold.

Two Seas Capital first reported a position in ESPR in Q2 2023 and held it in 12 quarters. The position peaked at $44M in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Two Seas Capital reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Two Seas Capital sold 11,394,833 Esperion Therapeutics shares in Q2 2026, an estimated $31.2M.
  • Two Seas Capital first reported a position in Esperion Therapeutics in Q2 2023 and held it in 12 quarters.
  • Two Seas Capital's Esperion Therapeutics position peaked at $44M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Two Seas Capital's 13F filing for Q2 2026, filed 12 Aug 2026.